Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
48 hedge funds and large institutions have $102M invested in Cidara Therapeutics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more funds holding
Funds holding: 42 → 48 (+6)
12% more capital invested
Capital invested by funds: $90.9M → $102M (+$10.7M)
0.36% more ownership
Funds ownership: 3.33% → 3.69% (+0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$7.28M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.07M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$2.09M |
| 4 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$396K |
| 5 |
Renaissance Technologies
New York
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$751K |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$698K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$521K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$231K |
| 5 |
Squarepoint
New York
|
-$167K |
CDTX Hedge Fund Activity: Q4 2017 in Review
48 of the 4,418 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2017, worth a combined $102M — up 12% from $90.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CDTX positions and 4 closed out — a net gain of 6 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was BB Biotech, adding an estimated $7.28M. The largest seller was Deutsche Bank, cutting an estimated $751K.
- 48 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2017, up from 42 in Q3 2017.
- Funds reported $102M of Cidara Therapeutics stock for Q4 2017, up 12% quarter-over-quarter.
- 10 funds opened new Cidara Therapeutics positions in Q4 2017 and 4 closed out, a net change of +6 holders.
- The largest Cidara Therapeutics buyer in Q4 2017 was BB Biotech, an estimated $7.28M added.
- The largest Cidara Therapeutics seller in Q4 2017 was Deutsche Bank, an estimated $751K sold.
Based on aggregated 13F filings for Q4 2017.